Amazon’s new GLP-1 pricing is dragging Novo Nordisk and Eli Lilly stocks lower.
Amazon Just Put the Biggest Trade of the Decade on the Wrong Side—and Big Pharma Is Paying for It
Phil Rosen·Inc. Magazine··1 min read
I
Continue reading on Inc. Magazine
This article was sourced from Inc. Magazine's RSS feed. Visit the original for the complete story.